## University of Massachusetts Medical School eScholarship@UMMS

COVID-19 Publications by UMMS Authors

2021-05-18

# Myocarditis following COVID-19 vaccination

Elisabeth Albert University of Massachusetts Medical School

Et al.

# Let us know how access to this document benefits you.

Follow this and additional works at: https://escholarship.umassmed.edu/covid19

Part of the Cardiology Commons, Cardiovascular Diseases Commons, Infectious Disease Commons, Radiology Commons, and the Virus Diseases Commons

### **Repository Citation**

Albert E, Aurigemma GP, Saucedo J, Gerson DS. (2021). Myocarditis following COVID-19 vaccination. COVID-19 Publications by UMMS Authors. https://doi.org/10.1016/j.radcr.2021.05.033. Retrieved from https://escholarship.umassmed.edu/covid19/242

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License. This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in COVID-19 Publications by UMMS Authors by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.

## Journal Pre-proof

Myocarditis following COVID-19 vaccination

Elisabeth Albert MD, FRCPC, Gerard Aurigemma MD, Jason Saucedo MD, David S. Gerson MD

 PII:
 S1930-0433(21)00328-9

 DOI:
 https://doi.org/10.1016/j.radcr.2021.05.033

 Reference:
 RADCR 2094



Received date:6 May 2021Revised date:10 May 2021Accepted date:10 May 2021



Please cite this article as: Elisabeth Albert MD, FRCPC, Gerard Aurigemma MD, Jason Saucedo MD, David S. Gerson MD, Myocarditis following COVID-19 vaccination, *Radiology Case Reports* (2021), doi: https://doi.org/10.1016/j.radcr.2021.05.033

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) Myocarditis following COVID-19 vaccination

Authors names and affiliations Elisabeth Albert, MD, FRCPC<sup>a</sup> Gerard Aurigemma, MD<sup>b</sup> Jason Saucedo, MD<sup>b</sup> David S. Gerson, MD<sup>a</sup>

<sup>a</sup> Department of Radiology University of Massachusetts Medical School, UMass Memorial Medical Center, 55 Lake avenue North, Worcester, 01655, MA, USA <sup>b</sup> Department of Medicine (Cardiovascular Medicine Division), University of Massachusetts Medical Center, UMass Memorial Medical Center, 55 Lake avenue North Worcester, 01655, MA, USA

Corresponding author Elisabeth Albert e-mail address <u>elisabeth.albert.1@ulaval.ca</u> phone number 1-418-265-7842 The coronavirus disease 2019 (COVID-19) vaccination frequently leads to minor sideeffects, that may be more intense after the second dose, but more serious side effects have been reported. We report a case of a 24-year-old man who presented to the hospital with acute substernal chest pain, 4 days after his second COVID-19 Moderna vaccination. Laboratory studies revealed elevated troponins and negative viral serologies. Cardiac magnetic resonance imaging (cMRI) demonstrated edema and delayed gadolinium enhancement of the left ventricle in a midmyocardial and epicardial distribution. The patient was diagnosed with myocarditis following Moderna vaccination. Our case report raises concern that myocarditis is a rare side effect of COVID-19 vaccine. Despite our report, it appears that there is a significantly higher risk of cardiac involvement from COVID-19 infection compared to COVID-19 vaccination.

#### Case presentation

A previously healthy 24-year-old man, with no past cardiac medical history, presented to emergency department with chest discomfort 4-days after his second dose of the Moderna COVID19 vaccine. Initially the patient experienced a subjective fevers, chills, and body aches in the first 24 hours after the shot. His symptoms progressed to a substernal chest pain, which was exacerbated with deep inspiration and supine position. The patient reported similar symptoms after the first vaccine administration, but these symptoms were not nearly as intense.

Investigations

The patient's electrocardiogram demonstrated a sinus rhythm without ischemic changes. Laboratory studies revealed: elevated troponin I (18.94ng/mL, normal 0.01- 0.04), elevated Creatine Kinase (704 U/L, normal 49-348), elevated C Reactive Protein (26.4 mg/L, normal <10.0) and negative PCR for COVID-19.

Viral studies, including Parvovirus B19, Ebstein-Barr virus, adenovirus, influenza, Herpes Simplex 1 and 2, Lyme antibody were all negative.

A Transthoracic echocardiogram 4 days post vaccination was within normal limits, the left ventricular ejection fraction (LVEF) was 65%. No focal wall motion abnormality was seen.

Computed tomographic angiography of the coronary arterial system 5 days postvaccination demonstrated a calcium score of 0 without coronary artery stenosis and small bilateral pleural effusions.

Cardiac MRI with gadolinium 5 days post-vaccination demonstrated normal LV size and EF (58%), patchy mid- myocardial and epicardial delayed gadolinium enhancement (Fig.1), with superimposed edema (Fig.1), fulfilling the Lake Louise criteria for myocarditis

#### Discussion

Vaccination is a well-established part of preventive and public health medicine, but is not without risk. COVID-19 vaccination frequently leads to minor side-effects, for example pain, swelling and redness at the site of injection, and systemic symptoms of fatigue, headache, muscle pain, chills and fever; side effects after the second dose may be more intense than the first dose[1]. Among the mRNA vaccines, including Pfizer-BioNTech and Moderna, more serious side effects have been reported, including myocarditis[2,3]. Myocarditis can range from mild asymptomatic inflammation of the heart to severe heart failure and death[4].

Viral infection has been described as one of the most common causes of myocarditis, especially associated with influenza and parvovirus B-19 infection. Myocarditis has been reported following many different vaccines, with the smallpox vaccine having the strongest association[5]. Due to the few cases of myocarditis reported post COVID-19 vaccine, little is known about this process.

The Israeli Ministry of Health reported 62 cases of myocarditis in patients vaccinated for COVID-19 out of 5 million vaccinated individuals. Most cases occurred after the second dose of mRNA vaccines, with only 6 cases diagnosed after the first dose. The prevalence was higher in men under 30 years of age, increasing from 1/100 000 for the general population, to 1/20 000 for the 16-30 years old group. Two of the 62 patients died. The U.S. Department of Defense reported 14 military personnel diagnosed with myocarditis following COVID vaccination, 13 of them after their second dose of COVID-19 mRNA vaccines. Three of the personnel received Pfizer/BioNTech vaccine, and 11 had received the Moderna vaccine, with an occurrence of 0.52/100 000 among the 2.7 million military personnel vaccinated[2,3].

At time of writing, neither the FDA nor CDC have reported any safety signals for myocarditis following the administration of the approved COVID-19 vaccines[6]. At present time, there are no reports in the scientific literature reporting notion of myocarditis related to COVID-19 vaccination.

There are specific indications for cardiac MRI in suspected myocarditis case including currently symptomatic cases, evidence of myocardial damage and suspected viral or autoimmune etiologies[7,8]. The diagnosis of myocarditis can be confirmed by cardiac MRI. Two criteria have been developed – the Original and the 2018 Lake Louise Criteria for the diagnosis of acute myocarditis. In the original criteria, two out of three elements are needed for diagnosis. The three elements are: (1) regional or global myocardial signal intensity increase on T2-weighted images; (2) increased global myocardial early gadolinium enhancement ratio; (3) at least one focal, nonischemic lesion at late gadolinium enhancement. In the revised 2018 Lake Louise criteria, both (1) regional or global myocardial signal intensity and relaxation time increase on T2-weighted images and (2) increase native relaxation time and extracellular volume on T1-weighted images and nonischemic pattern late gadolinium enhancement are needed[7,8].

In summary, we recognize that vaccination is one of the greatest advancement in medicine in the previous century, and has significantly reduced the burden of infectious disease[9]. From Louis Pasteur, who developed the first laboratory vaccine in 1879, for chicken cholera[10], to the 21st century COVID-19 pandemic, untold disability and death has been prevented by vaccination[9]. Despite the demonstration of safety, and the endorsement of the World Health Organization, and other bodies that vaccines are far safer than therapeutic drugs, vaccines are not without risk[9]. Myocarditis is one of the serious adverse event of vaccination[5].

We believe that given the negative PCR test for COVID-19, as well as the negative viral serologies, myocarditis, in this instance, was due to the vaccine, rather than acute infection, but the latter possibility cannot be totally discounted. The mechanisms involved in such vaccine-related myocarditis are not clear as of this writing[11].

The patient has been discharged from hospital with beta-blocker medication. He was instructed to avoid strenuous activities for three months, as well as non-steroidal anti-inflammatory drugs (NSAID). The patient has a scheduled follow-up appointment with the cardiologist.

Conclusion

Despite the fact that myocarditis has been reported following many vaccines[5], further research will be needed to confirm the association of myocarditis post-COVID-19 vaccination. The data in hand suggest a small risk of myocarditis following infection [7,8,12], as well as thrombosis related myocardial infarction [13]. Thus despite our report, it appears that there is a significantly higher risk of cardiac involvement from COVID-19 infection compared to COVID-19 vaccination[12]. Accordingly, we believe that COVID-19 vaccination should remain the cornerstone for population immunity.

### Consent

Written, informed consent for publication of his case was obtained from the patient. written consent is retained by the authors.



Ε.

F.

Fig. 1. A and B: Short axis T2 images of the mid left ventricle showing hyperintense signal of the antero-lateral and infero-lateral segments. C and D: Short axis 10 minutes post-gadolinium injection of the mid left ventricle showing mid myocardial and epicardial enhancement in the same distribution. E : 4 chambers view T2 images showing hyperintense signal of the lateral wall of the left ventricle. F: 4 chambers view 10 minutes post-gadolinium injection showing enhancement in the same distribution.

### References

1.	Center for Disease Control and Prevention
	Possible Side Effects After Getting a COVID-19 Vaccine,
	Consulted on 05/02/2021
	https://www.cdc.gov/coronavirus/2019-
	ncov/vaccines/expect/after.html?s_cid=10509:side%20effects%20of%20covid%2019%20vaccine:
	sem.ga:p :RG:GM:gen:PTN:FY21
2.	Bruce Y. Lee
	Are rare cases of myocarditis linked to Pfizer, Moderna Covid-19 vaccines?
	Forbes, 04/27/2021
	https://www.forbes.com/sites/brucelee/2021/04/27/are-rare-cases-of-myocarditis-linked-to-pfizer-
2	modernacovid-19-vaccines/?sh=46c5951b/442
3.	Toi Staff
	Israel said probing link between Pfizer shot and heart problem in men under 30
	The Times of Israel, 04/23/2021
	nttps://www.timesonsraei.com/israei-said-probing-link-between-pilzer-snot-and-neart-problem-in-
4	Fung C. Luc H. Oiu V. Vang D.
4.	Fully G, Luo H, Qiu T, Tally D, McManus B. Myocarditis
	Circulation Research 2016:118:496-514 https://doi.org/10.1161/CIRCRESAHA.115.306573
5	Keinath K Church T Kurth B Hulten F
5.	Myocarditis secondary to smallpox vaccination
	BMJ Case rep. 2018:bcr2017223523, http://dx.doi.org/10.1136/bcr-2017-223523
6.	Michael Wilner.
	CDC, FDA see no Pfizer vaccine link to heart problem, eyeing with 'special interest'
	McClatchy, Consulted on 05/09/2021
	https://www.mcclatchydc.com/news/coronavirus/article250965424.html
7.	Friedrich M, Sechtem U, Schulz-Menger J, et al.
	Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper
	J Am Coll Cardiol. 2009; 53(17): 1475-1487 https://doi.org/10.1016/j.jacc.2009.02.007
8.	Maehara A.
	Consensus criteria for the diagnosis of myocarditis
	Consulted on 05/02/2021
	https://cdn.ymaws.com/scmr.org/resource/resmgr/2019/new_york/maehara, akiko -
0	<u>consensus c.pdt</u>
9.	Andre FE, Booy R, Bock HL, et al.
	Vaccination greatly reduces disease, disability, death and inequity worldwide
10	Bulletin of the world Health Organization. 2008;80(2)
10.	The bittery of Vaccines
	Consulted on 5/02/2021
	https://www.historyofyaccines.org/timeline#EVT_100871
11	Kim V Bae I Ryoo S Kim W
11.	Acute fulminant myocarditis following influenza vaccination requiring extracorporeal membrane
	oxygenation
	Acute Crit Care, 2019 : 34(2):165-169
12.	Imazio M, Klingel K, Kindermann I, et al.
	COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or
	myocarditis?
	Heart 2020;106:1127-3
13.	Hunter P
	Thrombosis after Covid-19 vaccination
	BMJ 2021;373:n958 https://doi.org/10.1136/bmj.n958